Akston Biosciences Corp filed a Form S-1 registration statement for an initial public offering on 2025-10-08. It has amended it 6 times. As of its latest filing, on 2026-05-04, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied to list our common stock on the NYSE American under the symbol “AXTN.” We believe that upon the completion of this offering, we will meet the standards for listing on the NYSE American, and the completion of this offering is contingent upon such listing.From the S-1/A filed 2026-05-04
Shares offered
We are offering 2,222,222 shares of our common stock.From the S-1/A filed 2026-05-04
Use of proceeds
We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents and short-term investments to complete renovation, build-out, and equipment installation at our new USDA manufacturing facility, manufacture and release pre-license serial batches of AKS-701d at our new USDA manufacturing facility, initiate a pivotal safety and efficacy study in dogs with bladder cancer to support conditional approval of AKS-701d, conduct pilot field efficacy studies in dogs with cancer, dermatitis, and pain using AKS-619d, AKS-699, and AKS-548d, develop manufacturing cell lines for our product candidates, including AKS-548d, complete pilot field…From the S-1/A filed 2026-05-04
Net loss or income
Our net loss for the year ended December 31, 2025, was $28.6 million and our net income for the year ended December 31, 2024, was $3.8 million.From the S-1/A filed 2026-05-04
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-10-08 | Registration statement filed | S-1 |
| 2025-11-17 | Registration statement amended | S-1/A |
| 2025-12-08 | Registration statement amended | S-1/A |
| 2026-01-15 | Registration statement amended | S-1/A |
| 2026-02-18 | Registration statement amended | S-1/A |
| 2026-04-10 | Registration statement amended | S-1/A |
| 2026-05-04 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for Akston Biosciences Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.